ArticleHaematologica2020
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07300514 (Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma in Complete or Partial Remission After First-Line Chemotherapy), which is not on this map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma in Complete or Partial Remission After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Phase III Clinical Study.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Asymmetry and redundancy of STAT5 paralogs across CD8Communications biology · 2026Article
- Targeting p16Leukemia · 2025Article
- Immunometabolic Dysregulation in B-Cell Acute Lymphoblastic Leukemia Revealed by Single-Cell RNA Sequencing: Perspectives on Subtypes and Potential Therapeutic Targets.International journal of molecular sciences · 2025Article
- Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.Leukemia · 2025Review
- JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders.Frontiers in immunology · 2025Review
- Article
- Roles of Growth Hormone-Dependent JAK-STAT5 and Lyn Kinase Signaling in Determining Lifespan and Cancer Incidence.Endocrinology · 2024Article
- Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia.ACS pharmacology & translational science · 2024Article
- STAT5B SH2 variants disrupt mammary enhancers and the stability of genetic programs during pregnancy.bioRxiv : the preprint server for biology · 2024Article
- Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.The Journal of clinical investigation · 2024Article
- JAK/STAT in leukemia: a clinical update.Molecular cancer · 2024Review
- Signal Transducer and Activator of Transcription Proteins at the Nexus of Immunodeficiency, Autoimmunity and Cancer.Biomedicines · 2023Review
- A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.Nature chemical biology · 2023Article
- Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells.The Journal of clinical investigation · 2023Article
- STAT proteins in cancer: orchestration of metabolism.Nature reviews. Cancer · 2023Review
- Obesity and Risk for Lymphoma: Possible Role of Leptin.International journal of molecular sciences · 2022Review
- PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.Molecular cancer · 2022Article
- Recent research on the association between signal transducer and activator of transcription 5 and childhood acute lymphoblastic leukemia.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Review
- An OGT-STAT5 Axis in Regulatory T Cells Controls Energy and Iron Metabolism.Frontiers in immunology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 12 institutions in 4 countries.
Barbara MaurerLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Harini NivarthiCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Bettina WingelhoferLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Ha Thi Thanh PhamLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Michaela SchledererLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Tobias SuskeInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria.
Reinhard GrausenburgerInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
Ana-Iris SchieferDepartment of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Michaela Prchal-MurphyInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
Doris ChenCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Susanne WinklerLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Olaf MerkelDepartment of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Christoph KornauthDepartment of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Maximilian HofbauerLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Birgit HochgattererLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Gregor HoermannDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Andrea Hoelbl-KovacicInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
Jana ProchazkovaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Cosimo LobelloCentral European Institute of Technology (CEITEC), Center of Molecular Medicine, Masaryk University, Brno, Czech Republic.
Abbarna A CumaraswamyDepartment of Chemistry, University of Toronto Mississauga, Mississauga, Ontario, Canada.
Johanna LatzkaKarl Landsteiner Institute of Dermatological Research, St. Poelten, Austria and Department of Dermatology and Venereology, Karl Landsteiner University for Health Sciences, St. Poelten, Austria.
Melitta KitzwögererDepartment of Clinical Pathology, Karl Landsteiner University of Health Sciences, St. Poelten, Austria.
Andreas ChottInstitute of Pathology and Microbiology, Wilheminenspital, Vienna, Austria.
Andrea JanikovaDepartment of Internal Medicine - Hematology and Oncology, Faculty of Medicine Masaryk University and University Hospital Brno, Brno, Czech Republic.
Šárka PospíšilovaCentral European Institute of Technology (CEITEC), Center of Molecular Medicine, Masaryk University, Brno, Czech Republic.
Joanna I LoizouCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Stefan KubicekCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Peter ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Thomas KolbeBiomodels Austria, University of Veterinary Medicine Vienna, Vienna, Austria.
Florian GrebienLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Lukas KennerLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Patrick T GunningCentral European Institute of Technology (CEITEC), Center of Molecular Medicine, Masaryk University, Brno, Czech Republic.
Robert KralovicsCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Marco HerlingDepartment I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Mathias MüllerInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria.
Thomas RülickeInstitute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.
Veronika SexlInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria.
Richard MorigglLudwig Boltzmann Institute for Cancer Research, Vienna, Austria richard.moriggl@vetmeduni.ac.at.
University of Veterinary Medicine Vienna · ATMedical University of Vienna · ATLudwig Boltzmann Institute for Cancer Research · ATCeMM Research Center for Molecular Medicine · ATMasaryk University · CZAustrian Academy of Sciences · ATKarl Landsteiner University of Health Sciences · ATCentral European Institute of Technology · CZCologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DELudwig Boltzmann Cluster for Cardiovascular Research · ATUniversity of Toronto · CAWilhelminen Hospital · AT
Funding
Austrian Science Fund FWF I 4157
Abstract
Recurrent gain-of-function mutations in the transcription factors
Indexed as
LeukemiaLymphoma, T-Cell, PeripheralAnimalsCD8-Positive T-LymphocytesCytokinesHumansMiceSTAT5 Transcription FactorTumor Suppressor ProteinsCytokinesSTAT5A protein, humanSTAT5 Transcription FactorTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT07300514ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.